Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Book cover Arzneiverordnungs-Report 2003

Zusammenfassung

Unter Psychopharmaka werden verschiedene Gruppen von Arzneimitteln zusammengefaßt, die der Beeinflussung psychischer Erkrankungen dienen (Abbildung 41.1). Dazu zählen vier große Gruppen: Tranquillantien, die überwiegend von den Benzodiazepinen gestellt werden, Antidepressiva und Neuroleptika, wobei hier Präparate mit unterschiedlicher chemischer Struktur eingesetzt werden, sowie pflanzliche Psychopharmaka.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abraham J. (2003): The science and politics of medicines control. Drug Saf. 26:135–143.

    Article  PubMed  Google Scholar 

  • Apter J.T., Allen L.A. (1999): Buspirone: future directions. J. Clin. Psychopharmacol. 19: 86–93.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2002): BfArM-Bescheid zu Kava-Kava. Pharm. Ztg. 147: 6–7.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg.) (1997): Empfehlungen zur Therapie der Depression. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis. September 1997.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg.) (2000): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2001): Hepatotoxizität des neuen Antidepressivums Nefazodon (Nefadar®). Dtsch. Ärztebl. 98: B52.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2002): Olanzapin: hyperosmolares Coma diabeticum, Rhabdomyolyse, Niereninsuffizienz. Dtsch. Ärztebl. 99:A741.

    Google Scholar 

  • Baptista T., Lacruz A., Angeles F., Silvera R., de Mendoza S., Mendoza M.T. et al. (2001): Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34: 223–231.

    Article  PubMed  CAS  Google Scholar 

  • Barbenel D.M., Yusufi B., O’Shea D., Bench C.J. (2000): Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J. Psychopharmacol. 14: 84–86.

    Article  PubMed  CAS  Google Scholar 

  • Barbui C, Hotopf M. (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit. J. Psychiatry 178: 129–144.

    Article  CAS  Google Scholar 

  • Barbui C, Hotopf M., Freemantle N., Boynton J., Churchill R., Eccles M.P. et al. (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst. Rev. 2000(4):CD002791.

    Google Scholar 

  • Bauer M., Dopfner S. (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol. 19: 427–434.

    Article  PubMed  CAS  Google Scholar 

  • Baumann P. (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31: 444–469.

    Article  PubMed  CAS  Google Scholar 

  • Benkert O., Szegedi A., Kohnen R. (2000): Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry 61: 656–663.

    Article  PubMed  CAS  Google Scholar 

  • Berlin I., Lecrubier Y. (1996): Food and drug interactions with monoamine oxidase inhibitors: How safe are the newer agents? CNS Drugs 5: 403–413.

    Article  CAS  Google Scholar 

  • Berner M.M., Riemann D., Berger M. (2002): The efficacy of hypericum extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression — a systematic review and analysis of randomized controlled trials. Eur. Arch. Psychiatry Clin. Neurosa. 252(suppl. l):P230 (Abstract).

    Google Scholar 

  • Blin O. (1999): A comparative review of new antipsychotics. Can. J. Psychiatry 44: 235–244.

    PubMed  CAS  Google Scholar 

  • Bon S., Hartmann K., Kuhn M. (1999): Johanniskraut: Ein Enzyminduktor? Schweiz. Ap. Ztg. 16: 535–536.

    Google Scholar 

  • Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N., Asghar S.A., Hompland M. et al. and the Lamictal 606 Study Group (2003): A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60: 392–400.

    Article  PubMed  CAS  Google Scholar 

  • Braun M., Strasser R.H. (1997): Trizyklische Antidepressiva und kongestive Kardiomypathie. Der Internist 38: 1236–1238.

    PubMed  CAS  Google Scholar 

  • Caley C.E, Weber S.S. (1995): Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann. Pharmacother. 29: 152–160.

    PubMed  CAS  Google Scholar 

  • Carrièr e P., Bonhomme D., Lemperiere T. (2000): Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur. Psychiatry 15: 321–329.

    Article  Google Scholar 

  • Carter CS., Mulsant B.H., Sweet R.A., Maxwell R.A., Coley K. et al. (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol. Bull. 31: 719–725.

    PubMed  CAS  Google Scholar 

  • Carvajal G.P., Garcia D., Sanchez S.A., Velasco M.A., Rueda D., Lucena M.L. (2002): Hepatotoxicity associated with the new antidepressants. Clin. Psychiatry 63: 135–137.

    Article  Google Scholar 

  • Chick J., Howlett H., Morgan M.Y., Ritson B. (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.

    PubMed  CAS  Google Scholar 

  • Chouinard G., Jones B., Remington G., Bloom D., Addington D. et al. (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13: 25–40.

    Article  PubMed  CAS  Google Scholar 

  • Colonna L., Saleem P., Dondey-Nouvel L., Rein W. (2000): Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol. 15: 13–22.

    Article  PubMed  CAS  Google Scholar 

  • Csernansky J.G., Mahmoud R., Brenner R. (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346: 16–22.

    Article  CAS  Google Scholar 

  • Dardennes R.,E ven C, Bange F., Heim A. (1995): Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders — a metaanalysis. Brit. J. Psychiat. 166:378–381.

    Article  PubMed  CAS  Google Scholar 

  • De Abajo F.J., Rodriguez L.A.G., Montero D. (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit. Med. J. 319: 1106–1109.

    Article  PubMed  Google Scholar 

  • De Smet P.A.G.M., Touw D.J. (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 575–576.

    Article  PubMed  Google Scholar 

  • Dettling M., Hellweg R., Cascorbi L, Deichle U., Weise L., Müller-Oerlinghausen B. (1999): Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 32: 32: 110–112.

    Article  Google Scholar 

  • Di Carlo G., Borreli F., Ernst E., Izzo A.A. (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol. Sci. 22: 292–297.

    Article  PubMed  Google Scholar 

  • Dinan T.G. (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit. Med. J. 324: 988–989.

    Article  Google Scholar 

  • Donovan S., Clayton A., Beeharry M., Jones S., Kirk C, Waters K. et al. (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br. J. Psychiatry 177: 551–556.

    Article  PubMed  CAS  Google Scholar 

  • Duggan L., Fenton M., Dardennes R.M., El-Dosoky A., Indran S. (2000): Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2: CD001359.

    PubMed  Google Scholar 

  • Einarson T.R., Arikian S.R., Casciano J., Doyle J.J. (1999): Comparison of extendedrelease venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin. Ther. 21: 296–308.

    Article  PubMed  CAS  Google Scholar 

  • Elliger T., Englert E., Freisleder F.J., Friedrich M., Gierow B. et al. (1994): Zur Behandlung schizophrener Psychosen des Kindes-und Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994, Kinder und Jugendpsychiatrie. Z. Kinder-Jugendpsychiat. 22: 325–327.

    Google Scholar 

  • Elliger T.J., Trott G.E., Nissen G. (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E. (2000): Second thoughts about safety of St. John’s wort. Lancet 354: 2014–2016.

    Article  Google Scholar 

  • Franchini L., Zanardi R., Gasperini M., Perez J., Smeraldi E. (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J. Affect. Disord. 38: 67–69.

    Article  CAS  Google Scholar 

  • Frank E., Kupfer DJ., Perel J.M. (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47: 1093–1099.

    Article  PubMed  CAS  Google Scholar 

  • Gale C, Oakley-Browne M. (2000): Anxiety disorder. Brit.Med. J. 321: 1204–1207.

    Article  PubMed  CAS  Google Scholar 

  • Geddes J., Freemantle N., Harrison P. et al. (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit. Med. J. 321: 1371–1376.

    Article  PubMed  CAS  Google Scholar 

  • Gelenberg A.J., Lydiard R. B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. (2000): Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 3082–3088.

    Article  PubMed  CAS  Google Scholar 

  • Goldstein J.M. (2000): The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychopharmacol. 3: 339–349.

    Article  CAS  Google Scholar 

  • Goodnick P.J., Barrios C.A. (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin. Pharmacother. 2: 667–680.

    Article  PubMed  CAS  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N., Engel R.R., Czernik A. et al. (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J. Affect. Disord. 40: 179–190.

    Article  PubMed  CAS  Google Scholar 

  • Guelfí J.D., Ansseau M., Timmerman L., Korsgaard S. (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J. Clin. Psychopharmacol. 21: 425–431.

    Article  PubMed  Google Scholar 

  • Guzelcan Y., Schölte W.F., Assies J., Becker H.E. (2001): Mania during the use of a combination preparation with St. John’s wort (Hypericum perforatum). Ned. Tijdschr. Geneeskd. 6: 1943–1945.

    Google Scholar 

  • Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287: 1807–1814.

    Article  Google Scholar 

  • Johne A., Brockmöller J., Bauer S., Maurer A., Langheinrich M., Roots I. (1999): Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66: 338–345.

    Article  PubMed  CAS  Google Scholar 

  • Johne A., Schmider J., Brockmöller J., Stadelmann A.M., Stormer E., Bauer S. et al. (2002): Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J. Clin. Psychopharmacol. 22: 46–54.

    Article  PubMed  CAS  Google Scholar 

  • Kane J., Honigfeld G., Singer J., Meltzer H. (1988): Clozapine for the treatmentresistant schizophrenic. Arch. Gen. Psychiatry 45: 789–796.

    Article  PubMed  CAS  Google Scholar 

  • Kappler J., Menges C, Ferbert A., Ebel H. (1994): Schwere „Spät“dystonie nach „Neuroleptanxiolyse“ mit Fluspirilen. Nervenarzt 65: 66–68.

    PubMed  CAS  Google Scholar 

  • Kasper S. (1996): Mirtazapin. Klinisches Profil eines noradrenalin-und serotoninspezifischen Antidepressivums. Arzneimitteltherapie 14 (9): 257–259.

    Google Scholar 

  • Kimko H.C., Cross J.T., Abernethy D.R. (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin. Pharmakokinet. 37: 457–470.

    Article  CAS  Google Scholar 

  • Kornhuber J. (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P., Laux G., Pöldinger W. (Hrsg.): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.

    Google Scholar 

  • Laakmann G., Schule C, Baghai T., Kieser M. (1998): St. John’s wort in mild to moderate depression: The relevance of hyperforin for clinical efficacy. Pharmacopsychiatry 31(SuppL): 54–59.

    Article  PubMed  CAS  Google Scholar 

  • Laties A.M. (2002): Quetiapine and cataracts. Am. J. Psychiatry 159: 322–323.

    Article  PubMed  Google Scholar 

  • Laux G. (2001): Cost benefit analysis of newer vs. older antidepressants. Pharmacopsychiatry 34: 1–5.

    Article  PubMed  CAS  Google Scholar 

  • Laux G., Volz H.-P., Möller H.-J. (1995): Newer and older monoamine oxidase inhibitors. CNS Drugs 3: 145–158.

    Article  CAS  Google Scholar 

  • Lantz M.S., Buchalter E., Giambanco V. (1999): St. John’s wort and antidepressant drug interactions in the elderly. J. Geriatr. Psychiatry Neurol. 12: 7–10.

    Article  PubMed  CAS  Google Scholar 

  • Lehmann K., Müller-Oerlinghausen B. (1993): Kosten-/Nutzen-Kalkulation der Lithium-Langzeit-Prophylaxe. Klin. Pharmakol. Aktuell 4: 68–70.

    Google Scholar 

  • Lepine J.P., Gastpar M., Mendlewicz J., Tylee A. (1997): Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12: 19–29.

    Article  PubMed  CAS  Google Scholar 

  • Lesch O.M., Riegler A., Gutierrez K., Hertling L, Ramskogler K., Semler B. et al. (2001): The European acamprosate trials. Conclusions for research and therapy. J. Biomed. Sci. 8: 89–95.

    Article  PubMed  CAS  Google Scholar 

  • Leucht S., Wahlbeck K., Hamann J., Kissling W. (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581–1589.

    Article  PubMed  CAS  Google Scholar 

  • Linde K., Mulrow CD. (2000): St. John’s wort for depression. Cochrane Database Syst. Rev. 2000(2): CD000448.

    Google Scholar 

  • Linde K., Ramirez G., Mulrow CD., Pauls A., Weidenhammer W., Melchart D. (1996): St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. Brit. Med. J. 313: 253–258.

    Article  PubMed  CAS  Google Scholar 

  • Linden M., Gothe, H. (1993): Benzodiazepine substitution in medical practice. Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry 26: 107–113.

    Article  PubMed  CAS  Google Scholar 

  • MacGillivray S., Arroll B., Hatcher S., Ogston S., Reid L, Sullivan F. et al. (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit. Med. J. 326:1014–1019.

    Article  PubMed  CAS  Google Scholar 

  • Macritchie K.A.N., Geddes M.R., Scott J., Haslam D.R.S., Goodwin G.M. (2001): Valproic acid, Valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • Marder S.R., Meibach R.C (1994): Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151: 825–835.

    CAS  Google Scholar 

  • Möller H.-J. (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4): 99–107.

    Article  PubMed  Google Scholar 

  • Möller H.-J., Volz H.P., Reimann I.W., Stoll K.D. (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J. Clin. Psychopharmacol. 21: 59–65.

    Article  PubMed  Google Scholar 

  • Moncrieff J. (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J. Nerv. Ment. Dis. 189: 288–295.

    Article  PubMed  CAS  Google Scholar 

  • Montgomery S.A., Roberts A., Patel A.G. (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int. Clin. Psychopharmacology 9: 49–53.

    Article  Google Scholar 

  • Moore L. B., Goodwin B., Jones S.A., Wisely G. B., Serabjit-Singh C.J., Willson T.M. et al. (2000): St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Nati. Acad. Sci. USA 97: 7500–7502.

    Article  CAS  Google Scholar 

  • Moses E.L., Mallinger A.G. (2000): St. John’s wort: three cases of possible mania induction. J. Clin. Psychopharmacol. 20: 115–117.

    Article  PubMed  CAS  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiat. 56: 1073–1086.

    Article  Google Scholar 

  • Müller-Oerlinghausen B. (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch. Ärztebl. 98: A1625–A1627.

    Google Scholar 

  • Müller-Oerlinghausen B., Berghöfer A. (1999): Antidepressants and suicidal risk. J. Clin. Psychiatry 60(suppl. 2): S94–S99.

    Google Scholar 

  • Müller-Oerlinghausen B., Berghöfer A., Bauer M. (2002): Bipolar disorder. Lancet 359:241–247.

    Article  PubMed  Google Scholar 

  • Miiller-Oerlinghausen B., Greil W, Berghöfer A. (Hrsg.) (1997): Die Lithiumtherapie. Nutzen Risiken Alternativen. Springer-Verlag, Berlin Heidelberg New York.

    Google Scholar 

  • Nierenberg A.A., Burt T., Matthews J., Weiss A.Pl. (1999): Mania associated with St. John’s wort. Biol. Psychiatry 46: 1707–1708.

    CAS  Google Scholar 

  • Olfson M., Marcus S.C., Pincus H.A., Zito J.M., Thompson J.W., Zarin D.A. (1998): Antidepressant prescribing practices of outpatient psychiatrists. Arch. Gen. Psychiatry 55: 310–316.

    Article  PubMed  CAS  Google Scholar 

  • Parker V., Wong A.H., Boon H.S., Seeman M.V. (2001): Adverse reactions to St John’s wort. Can. J. Psychiatry 46: 77–79.

    PubMed  CAS  Google Scholar 

  • Philipp M., Kohnen R., Hiller K.O. (1999): Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Brit. Med. J. 319: 1534–1538.

    Article  PubMed  CAS  Google Scholar 

  • Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falloon J. (2000): Indinavir concentrations and St John’s wort. Lancet 355: 547–548.

    Article  PubMed  CAS  Google Scholar 

  • Rickels K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry 63(Suppl. 14): 9–16.

    PubMed  CAS  Google Scholar 

  • Riederer P., Laux G., Pöldinger W. (Hrsg.) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.

    Google Scholar 

  • Rüther E., Ahrens B., Dieterle D., Erzgikeit A., Gaertner HJ. et al. (1995): Das Asolo Schema zur therapierelevanten multidimensionalen Klassifizierung der Antidepressiva. Psychopharmakothérapie 2: 158–164.

    Google Scholar 

  • Ruschitzka F., Meier P.J., Turina M., Lüscher T.E, Noll G. (2000): Acute heart transplant rejection due to Saint John’s wort. Lancet 355: 548–549.

    Article  PubMed  CAS  Google Scholar 

  • Safer DJ. (2000): Are stimulants overprescribed for youths with ADHD? Ann. Clin. Psychiatry 12: 55–62.

    CAS  Google Scholar 

  • Schnyder U., Koller-Leiser A. (1996): A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can. J. Psychiatry 41: 239–44.

    PubMed  CAS  Google Scholar 

  • Schou M. (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.

    Article  PubMed  CAS  Google Scholar 

  • Schrader E. (2000): Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 15: 61–68.

    Article  PubMed  CAS  Google Scholar 

  • Schulz V., Hansel R. (Hrsg.) (1996): Rationale Phytotherapie. Ratgeber für die ärztliche Praxis. Springer-Verlag, Berlin Heidelberg New York.

    Google Scholar 

  • Shelton R.C., Keller M. B., Gelenberg A., Dünner D.L., Hirschfeld R., Thase M.E. et al. (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285: 1978–1986.

    Article  PubMed  CAS  Google Scholar 

  • Smith D., Dempster C, Glanville J., Freemantle N., Anderson I. (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J Psychiatry 180: 396–404.

    Article  PubMed  Google Scholar 

  • Snow V, Lascher S., Mottur-Pilson C, for the American College of Physicians — American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann. Int. Med. 132: 739–742.

    Google Scholar 

  • Spigset O., Hagg S., Bate A. (2003): Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharmacol. 18: 157–161.

    PubMed  Google Scholar 

  • Sramek J.J., Zarotsky V., Cutler N.R. (2002): Generalized anxiety disorder: treatment options. Drugs 62: 1635–1648.

    Article  PubMed  CAS  Google Scholar 

  • Stewart D.E. (2002): Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry 47: 375–377.

    PubMed  Google Scholar 

  • Stip E. (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J. Psychiatry Neurosci. 25: 137–153.

    CAS  Google Scholar 

  • Sugimoto K., Ohmori M., Tsuruoka S., Nishiki K., Kawaguchi A., Harada K. et al. (2001): Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 70: 518–524.

    Article  PubMed  CAS  Google Scholar 

  • Swift R.M. (1999): Drug therapy for alcohol dependence. N. Engl. J. Med. 340: 1482–1490.

    Article  PubMed  CAS  Google Scholar 

  • Tandon R., Jibson M.D. (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    Article  PubMed  CAS  Google Scholar 

  • Taylor D.M., McAskill R. (2000): Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr. Scand. 101: 416–432.

    Article  PubMed  CAS  Google Scholar 

  • Tempesta E., Janiri L., Bignamini A., Chabac S., Potgieter A. (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.

    PubMed  CAS  Google Scholar 

  • Thase M.E. (2003): Effectiveness of antidepressants: comparative remission rates. J. Clin. Psychiatry 64 (Suppl. 2): 3–7.

    Article  CAS  Google Scholar 

  • Thase M.E., Entsuah R., Rudolph R.L. (2001): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br. Psychiatry 178: 234–241.

    Article  CAS  Google Scholar 

  • Thase M.E., Nierenberg A.A., Keller M. B., Panagides J. (2001): Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry 62: 782–788.

    Article  PubMed  CAS  Google Scholar 

  • Trindade E., Menon D., Topfer L.A., Coloma C. (1998): Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Canad. Med. Ass. J. 159: 1245–1252.

    CAS  Google Scholar 

  • Van Walraven C, Mamdani M.M., Wells P.S., Williams J.I. (2001): Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit. Med. J. 323: 1–6.

    Article  Google Scholar 

  • Volz H.P., Gleiter C.H., Möller HJ. (1996): Monoaminoxidasehemmer in der Psychiatric Nervenarzt 67: 339–347.

    PubMed  CAS  Google Scholar 

  • Volz H., Möller H., Reimann I., Stoll K. (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur. Neuropsychopharmacol. 10: 211–217.

    Article  PubMed  CAS  Google Scholar 

  • Von Ferber L., Lehmkuhl G., Köster I., Döpfner M., Schubert L, Frölich J., Ihle P. (2003): Methylphenidatgebrauch in Deutschland. Dtsch. Ärztebl. 100: C38–C43.

    Google Scholar 

  • Walsh B.T., Seidman S.N., Sysko R., Gould M. (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287: 1840–1847.

    Article  PubMed  Google Scholar 

  • Wang Z., Hamman M.A., Huang S.M., Lesko L.J., Hall S.D. (2002): Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther. 71: 414–420.

    Article  PubMed  CAS  Google Scholar 

  • Wetterling T. (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 24: 59–73.

    Article  CAS  Google Scholar 

  • Williams J.W.Jr., Mulrow CD., Chiquette E., Hitchcock Noël P., Aguilar C, Cornell J. (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann. Intern. Med. 132:743–756.

    PubMed  CAS  Google Scholar 

  • Woelk H. (2000): Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. Brit. Med. J. 321: 536–539.

    Article  PubMed  CAS  Google Scholar 

  • Woods J.H., Winger G. (1995): Current benzodiazepine issues. Psychopharmacology 118:107–115.

    Article  PubMed  CAS  Google Scholar 

  • Yue Q.-Y., Bergquist C, Gerdén B. (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 576–577.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Lorenzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universitat Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Lorenzen, A., Müller-Oerlinghausen, B. (2004). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18512-0_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40188-9

  • Online ISBN: 978-3-642-18512-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation